VivoSim Labs Operating Income 2011-2025 | VIVS

VivoSim Labs operating income from 2011 to 2025. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.

VivoSim Labs Operating Income 2011-2025 | VIVS

VivoSim Labs operating income from 2011 to 2025. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$228.5B
Amgen (AMGN)$165.9B
Gilead Sciences (GILD)$140.8B
Vertex Pharmaceuticals (VRTX)$121.3B
Bristol Myers Squibb (BMY)$99.6B
CSL (CSLLY)$86.2B
GSK (GSK)$78.3B
Regeneron Pharmaceuticals (REGN)$61B
Alnylam Pharmaceuticals (ALNY)$42.8B
Argenex SE (ARGX)$36.2B
BioNTech SE (BNTX)$27.5B
Royalty Pharma (RPRX)$20.6B
Insmed (INSM)$19.6B
Biogen (BIIB)$19.4B
Illumina (ILMN)$17B
Genmab (GMAB)$15.2B
Genmab (GNMSF)$14.9B
Incyte (INCY)$13.6B
Moderna (MRNA)$13.2B
Exelixis (EXEL)$12.2B
BioMarin Pharmaceutical (BMRN)$11.5B
QIAGEN (QGEN)$11.4B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10.3B
Exact Sciences (EXAS)$9.2B
Bio-Techne Corp (TECH)$9.2B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.3B
Legend Biotech (LEGN)$8.1B
Roivant Sciences (ROIV)$7.7B